Latest Insider Transactions at Edgewise Therapeutics, Inc. (EWTX)
This section provides a real-time view of insider transactions for Edgewise Therapeutics, Inc. (EWTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Edgewise Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Edgewise Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 11
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+47.65%
|
$0
$0.71 P/Share
|
|
Sep 23
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
20,922
-86.55%
|
$564,894
$27.63 P/Share
|
|
Sep 23
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,922
+46.39%
|
$0
$0.71 P/Share
|
|
Sep 20
2024
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
7,162
-33.0%
|
$200,536
$28.29 P/Share
|
|
Sep 20
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-93.89%
|
$1,400,000
$28.37 P/Share
|
|
Sep 20
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+48.43%
|
$0
$0.71 P/Share
|
|
Sep 20
2024
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
75,000
-45.3%
|
$2,100,000
$28.88 P/Share
|
|
Sep 20
2024
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+46.09%
|
$0
$0.18 P/Share
|
|
Sep 20
2024
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
125,092
-58.42%
|
$3,502,576
$28.58 P/Share
|
|
Sep 20
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
96,068
+41.37%
|
$96,068
$1.93 P/Share
|
|
Sep 20
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
42,068
-73.56%
|
$1,219,972
$29.03 P/Share
|
|
Sep 20
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,068
+42.38%
|
$42,068
$1.93 P/Share
|
|
May 02
2024
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,157
-5.77%
|
$38,826
$18.91 P/Share
|
|
May 02
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,956
-37.56%
|
$35,208
$18.91 P/Share
|
|
May 02
2024
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
3,152
-17.88%
|
$56,736
$18.91 P/Share
|
|
May 02
2024
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
3,682
-15.62%
|
$66,276
$18.91 P/Share
|
|
May 02
2024
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,576
-17.88%
|
$28,368
$18.91 P/Share
|
|
May 02
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,718
-11.35%
|
$30,924
$18.91 P/Share
|
|
May 01
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+12.23%
|
-
|
|
May 01
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+50.0%
|
-
|
|
May 01
2024
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+37.14%
|
-
|
|
May 01
2024
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+30.64%
|
-
|
|
May 01
2024
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+37.14%
|
-
|
|
May 01
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+25.59%
|
-
|
|
Feb 09
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,800
-40.61%
|
$96,000
$20.04 P/Share
|
|
Feb 09
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,800
+28.88%
|
$4,800
$1.93 P/Share
|
|
Feb 09
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
8,029
-100.0%
|
$160,580
$20.01 P/Share
|
|
Feb 09
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,029
+50.0%
|
$8,029
$1.93 P/Share
|
|
Feb 08
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,600
-39.59%
|
$92,000
$20.01 P/Share
|
|
Feb 08
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+28.36%
|
$4,600
$1.93 P/Share
|
|
Feb 08
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
3,813
-100.0%
|
$76,260
$20.01 P/Share
|
|
Feb 08
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,813
+50.0%
|
$3,813
$1.93 P/Share
|
|
Feb 07
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
600
-7.87%
|
$12,000
$20.0 P/Share
|
|
Feb 07
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+7.3%
|
$600
$1.93 P/Share
|
|
Feb 07
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
17,993
-100.0%
|
$359,860
$20.0 P/Share
|
|
Feb 07
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
17,993
+50.0%
|
$17,993
$1.93 P/Share
|
|
Jan 23
2024
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
90,000
-75.62%
|
$1,350,000
$15.78 P/Share
|
|
Jan 23
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+43.06%
|
$90,000
$1.93 P/Share
|
|
Jan 23
2024
|
Peter A. Thompson |
BUY
Open market or private purchase
|
Indirect |
454,545
+3.05%
|
$4,999,995
$11.0 P/Share
|
|
Jan 23
2024
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
454,545
+3.05%
|
$4,999,995
$11.0 P/Share
|
|
Dec 27
2023
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
8,497
-100.0%
|
$84,970
$10.5 P/Share
|
|
Dec 26
2023
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
172,585
-97.95%
|
$1,553,265
$9.33 P/Share
|
|
Dec 26
2023
|
Jonathan C Fox |
BUY
Open market or private purchase
|
Direct |
10,857
+50.0%
|
$97,713
$9.3 P/Share
|
|
Jun 22
2023
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.63%
|
$0
$0.71 P/Share
|
|
May 02
2023
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
3,203
-30.75%
|
$25,624
$8.9 P/Share
|
|
May 02
2023
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
3,254
-24.63%
|
$26,032
$8.9 P/Share
|
|
May 02
2023
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,602
-0.9%
|
$12,816
$8.9 P/Share
|
|
May 02
2023
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,336
-7.65%
|
$10,688
$8.9 P/Share
|
|
May 02
2023
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,897
-22.42%
|
$15,176
$8.9 P/Share
|
|
May 02
2023
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,747
-19.93%
|
$13,976
$8.9 P/Share
|